BTOG 2024 | Evolving definitions of resectability in stage III lung cancer

Mariana Brandao, MD, PhD, Institute Jules Bordet in Brussels, Belgium, discusses the evolving landscape of defining resectability in stage III lung cancer. She highlights the challenges of standardizing criteria due to the heterogeneous nature of patient populations in clinical trials. Dr Brandao explains the initiative led by the Aortic Lung Cancer Group to establish a consensus definition of resectability for use in trials, involving collaboration from multiple medical specialties. She emphasizes the importance of thorough patient workup and multidisciplinary discussion in determining resectability. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.